Day: March 30, 2026

Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional data submitted to the U.S. FDA with the objective to discuss potential pathways towards a New Drug Application (NDA) for the treatment of early Alzheimer’s disease Additionally, Anavex has engaged in discussions with EU regulators regarding blarcamesine for Parkinson’s disease and rare diseases, including Rett syndrome NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other...

Intersection includes 23.9m of 1.72 g/t gold, 7.15m of 3.46 g/t gold, and 16m of 0.07 g/t gold* Exploration further expands gold mineralization at Juby Gold Project on Golden Lake Deposit TORONTO, March 30, 2026 (GLOBE NEWSWIRE) — McFarlane Lake Mining Limited (“McFarlane” or the “Company”) (CSE: MLM, OTC: MLMLF, FRA: W2Z) is pleased to announce further results from its diamond drilling exploration campaign being conducted on its 100%-owned Juby Gold Project, located west of Gowganda, Ontario, within the southern part of the “Abitibi Greenstone Belt”. Drilling was initiated in December 2025 on the property and commenced at the Company’s 826 Zone and has now moved to the Golden Lake Zone, see Figure 1. HighlightsDrill hole GL 76-72 at Golden Lake has intersepted 0.95 g/t gold over 92.6m, this includes 23.9m of 1.72 g/t gold and...

CALGARY, Alberta, March 30, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced it has secured non-dilutive funding from the Alberta Innovates CarE (AICE) market access program to support the Phase I testing of its lead compound, MB-204. The $600,000 AICE-funded project represents a significant contribution toward the overall cost of the Phase I clinical trial of MB-204 and supports the advancement of the program into human trials. The AICE program is highly competitive and subject to rigorous peer review, providing strong third-party validation of the scientific and commercial potential...

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patients High Dose SPINRAZA will be available in the United States in the coming weeks and is also approved in the European Union, Switzerland and JapanCAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of spinal muscular atrophy (SMA). Backed by more than 10 years of clinical data supporting the Low Dose Regimen of SPINRAZA (12 mg), High Dose SPINRAZA was designed to deliver a higher concentration of drug through...

Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading and every-three-week maintenance dose of ficerafusp alfa Corporate call to discuss financial results and business updates on Monday, March 30, 2026 at 8:30 a.m. ET BOSTON, March 30, 2026 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided a business update. “Bicara enters the year with exceptional momentum across our clinical, regulatory, and corporate priorities,” said Claire Mazumdar, Ph.D., Chief Executive Officer at Bicara Therapeutics. “The continued advancement of our pivotal FORTIFI-HN01 study, the robust body...

Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial design and treatment approaches Manuscript emphasizes the importance of early therapeutic intervention in children to help reduce the risk of more serious complications over time Review supports the scientific rationale of QTORIN™ 3.9% rapamycin anhydrous gel as a potential targeted therapy for microcystic lymphatic malformations WAYNE, Pa., March 30, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug...

Commercial agreement serves as high-profile third party validation of BullFrog AI’s proprietary capabilities Agreement utilizes BullFrog AI’s end-to-end analytical AI platform to accelerate drug discovery and development program GAITHERSBURG, Md., March 30, 2026 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, today announced a commercial agreement with a top 5 global pharmaceutical company in 2025 by revenue (“Customer”), to apply the Company’s proprietary bfLEAP® platform to identify and prioritize novel drug targets in major depressive disorder (MDD), accelerating the Customer’s drug discovery and clinical development program...

Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported independent clinical validation of its Phase 2 SkinJect® dataset from Dr. Babar Rao, principal investigator of the SKNJCT-003 study and a globally recognized dermatology key opinion leader.  Dr. Rao’s independent assessment reinforces the Company’s view that the dataset is clinically meaningful, decision-grade, and supportive of continued development and regulatory engagement. Dr. Rao, speaking...